Inhibition of DNA topoisomerase I activity by heparin sulfate and modulation by basic fibroblast growth factor (original) (raw)

References

  1. Gellert M: DNA topoisomerases. Ann Rev Biochem 50: 879–910, 1981
    Article PubMed Google Scholar
  2. Wang JC: DNA topoisomerases. Ann Rev Biochem 54: 665–697, 1985
    Article PubMed Google Scholar
  3. Stewart AF, Schültz G: Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene. Cell 50: 1109–1117, 1987
    Article PubMed Google Scholar
  4. Gilmour DS, Elgin SCR: Localization of specific topoisomerase I interactions within the transcribed region of active heat shock genes by using the inhibitor camptothecin. Mol Cell Biol 7: 141–148, 1987
    PubMed Google Scholar
  5. Zhang H, Wang JC, Liu LF: Involvement of DNA topisomerase I in transcription of human ribosomal RNA genes. Proc Natl Acad Sci USA 85: 1060–1064, 1988
    PubMed Google Scholar
  6. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SCR: Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81: 6958–6962, 1984
    PubMed Google Scholar
  7. Muller MT, Pfund WP, Mehta VB, Trask DK: Eukaryotic type I topoisomerase is enriched in the nucleolus and catalytically active on ribosomal DNA. EMBO J 4: 1237–1243, 1985
    PubMed Google Scholar
  8. Egyházi E, Durban E: Microinjection of anti-topoisomerase I immunoglobulin G into nuclei of chironomus tentans salivary gland cells leads to blockage of transcription elongation. Mol Cell Biol 7: 4308–4316, 1987
    PubMed Google Scholar
  9. Kim RA, Wang JC: Function of DNA topoisomerases as replication swivels in saccharomyces cerevisiae.J Mol Biol 208: 257–267, 1989
    Google Scholar
  10. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046–1048, 1989
    PubMed Google Scholar
  11. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH: The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 85: 271–291, 1993
    PubMed Google Scholar
  12. van der Zee AGJ, Hollema H, deJong S, Boonstra H, Gouw A, Willemse PHB, Zijistra JG, deVries EGE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915–5920, 1991
    PubMed Google Scholar
  13. van der Zee AGJ, deJong S, Keith WN, Hollema H, Boonstra H, deVries EGE: Quantitative and qualitative aspects of topoisomerase I and II03B1; and β in untreated and platinum/cyclophosphamide treated malignant ovarian tumors. Cancer Res 54: 749–755, 1994
    PubMed Google Scholar
  14. Matsumoto Y, Fujiwara T, Honjo Y, Sasaoka N, Tsuchida T, Nagao S: Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: Characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11. J Surg Oncol 53: 97–103, 1993
    PubMed Google Scholar
  15. Gromova II, Kjeldsen E, Svejstrup JQ, Aisner J, Christiansen K, Westergaard O: Characterization of an altered DNA catalysis of a camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res 21: 593–600, 1993
    PubMed Google Scholar
  16. Madelaine I, Prost S, Naudin A, Riou G, Lavelle F, Riou J-F: Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol 45: 339–348, 1993
    Article PubMed Google Scholar
  17. Camilloni G, Di Martino E, Caserta M, di Mauro E: Eukaryotic DNA topoisomerase I reaction is topology dependent. Nucleic Acids Res 16: 7071–7085, 1988
    PubMed Google Scholar
  18. Camilloni G, Di Martino E, di Mauro E, Caserta M: Regulation of the function of eukaryotic DNA topoisomerase I: Topological conditions for inactivity. Proc Natl Acad Sci USA 86: 3080–3084, 1989
    PubMed Google Scholar
  19. Stewart L, Ireton GC, Parker LH, Madden KR, Champoux JJ: Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 271: 7593–7601, 1996
    Article PubMed Google Scholar
  20. Samuels DS, Shimizu Y, Shimizu N: Protein kinase C phosphorylates DNA topoisomerase I. FEBS Lett 259: 57–60, 1989
    Article PubMed Google Scholar
  21. Pommier Y, Kerrigan D, Hartman KD, Glazer RI: Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem 265: 9418–9422, 1990
    PubMed Google Scholar
  22. Esther A, Iftach S, Esther P: Inhibition of moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors. FEBS Lett 341: 99–103, 1994
    Article PubMed Google Scholar
  23. Krupitza G, Cerutti P: ADP-ribosylation of ADPR-transferase and topoisomerase I in intact mouse epidermal cells JB6. Biochemistry 28: 2034–2040, 1989
    PubMed Google Scholar
  24. Rossi F, Labourier E, Forné T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunel C, Tazi J: Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 381: 80–82, 1996
    Article PubMed Google Scholar
  25. Ishii K, Katase A, Andoh T, Seno N: Inhibition of topoisomerase I by heparin. Biochem Biophys Res Commun 104: 541–547, 1982
    PubMed Google Scholar
  26. Anderiuzzi D, Pedrini AM: Structural similarities between M. luteus and E. coli DNA topoisomerase I. Biochem Biophys Res Comm 192: 657–664, 1993
    Article PubMed Google Scholar
  27. Ishihara M, Fedarko NS, Conrad HE: Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem 261: 13575–13580, 1986
    PubMed Google Scholar
  28. Fedarko NS, Conrad HE: A unique heparan sulfate in the nuclei of hepatocytes: Structural changes with the growth state of the cells. J Cell Biol 102: 587–599, 1986
    Article PubMed Google Scholar
  29. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M: Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 51: 3951–3957, 1991
    PubMed Google Scholar
  30. Aviezer D, Levy E, Safran M, Svahn C, Buddecke E, Schmidt A, David G, Vlodavsky I, Yayon A: Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J Biol Chem 269: 114–121, 1994
    PubMed Google Scholar
  31. Fedarko NS, Ishihara M, Conrad HE: Control of cell division in hepatoma cells by exogenous heparan sulfate proteoglycan. J Cell Physiol 139: 287–294, 1989
    PubMed Google Scholar
  32. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL: Trans-repressor activity of nuclear glycosaminoglycans on fos and jun/AP-1 oncoprotein-mediated transcription. J Cell Biol 116: 31–42, 1992
    Article PubMed Google Scholar
  33. Grammatikakis N, Grammatikakis A, Yoneda M, Yu Q, Banerjee SD, Toole BP: A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37. J Biol Chem 270: 16198–16205, 1995
    Article PubMed Google Scholar
  34. Esko JD: Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol 3: 805–816, 1991
    Article PubMed Google Scholar
  35. Tyrrell DJ, Ishihara M, Rao N, Home A, Kiefer MC, Stauber GB, Lam LH, Stack RJ: Structure and biological activities for a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 268: 4684–4689, 1993
    PubMed Google Scholar
  36. Turnbull JE, Gallagher JT: Heparan sulphate: Functional role as a modulator of fibroblast growth factor activity. Biochem Soc Trans 21: 477–482, 1993
    PubMed Google Scholar
  37. Faham S, Hileman RE, Fromm JP, Linhardt RJ, Rees DC: Heparin structure and interactions with basic fibroblast growth factor. Science 271: 1116–1120, 1996
    PubMed Google Scholar
  38. Kovalszky I, Pogány G, Molnár G, Jeney A, Lapis K, Karácsonyi S, Szécsény A, Iozzo RV: Altered glycosaminoglycans composition in reactive and neoplastic human liver. Biochem Biophys Res Comm 167: 883–890, 1990
    PubMed Google Scholar
  39. Debbage PL, Lange W, Hellmann T, Gabius HJ: Detection of receptors for sulfated polysaccharides in human placenta by biotinylated probes. J Histochem Cytochem 36: 1097–1102, 1988
    PubMed Google Scholar
  40. Murata K, Ochiai Y, Akashio K: Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 89: 1248–1257, 1985
    PubMed Google Scholar
  41. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976
    Article PubMed Google Scholar
  42. Bitter T, Muir HM: A modified uronic acid carbazole reaction. Anal Biochem 4: 330–334, 1962
    PubMed Google Scholar
  43. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual. 2nd edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989
    Google Scholar
  44. Duguet M, Lavenot C, Harper F, Mirambeau G, De Recondo A-M: DNA topoisomerases from rat liver: Physiological variations. Nucleic Acids Res 11: 1059–1075, 1983
    PubMed Google Scholar
  45. Sullivan DM, Latham MD, Rowe TC, Ross WE: Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28: 5680–5687, 1989
    PubMed Google Scholar
  46. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685, 1970
    PubMed Google Scholar
  47. Volpi N, Cusmano M, Venturelli T: Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta 1243: 49–58, 1995
    PubMed Google Scholar
  48. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267: 10931–10934, 1992
    PubMed Google Scholar
  49. Iozzo RV, Bolender RP, Wight TN: Proteoglycan changes in the intercellular matrix of human colon carcinoma. Lab Invest 47: 124–138, 1982
    PubMed Google Scholar
  50. Iozzo RV, Cohen I: Altered proteoglycan gene expression and the tumor stroma. Experientia 49: 447–455, 1993
    PubMed Google Scholar
  51. Gallagher JT: The extended family of proteoglycans: Social residents of the pericellular zone. Curr Opin Cell Biol 1: 1201–1218, 1989
    PubMed Google Scholar
  52. Iozzo RV: Presence of unsulfated heparan chains on the heparan sulfate proteoglycan of human colon carcinoma cells. Implications for heparan sulfate proteoglycan biosynthesis. J Biol Chem 264: 2690–2699, 1989
    PubMed Google Scholar
  53. Esko JD, Rostand KS, Weinke JL: Tumor formation dependent on proteoglycan biosynthesis. Science 241: 1092–1096, 1988
    PubMed Google Scholar
  54. Hiscock DR, Yanagishita M, Hascall VC: Nuclear localization of glycosaminoglycans in rat ovarian granulosa cells. J Biol Chem 287–294, 1989
  55. Moczar E, Raulais D, Poupon MF, Moczar M: Heparin-binding sites of rhabdomyoma cells with low and high metastatic capacity. Invasion Metastasis 11: 158–165, 1991
    PubMed Google Scholar
  56. Sanderson RD, Tumbull JE, Gallagher JT, Lander AD: Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J Biol Chem 269: 13100–13106, 1994
    PubMed Google Scholar
  57. Lee MK, Lander AD: Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: Development of a sensitive electrophoretic approach. Proc Natl Acad Sci USA 88: 2768–2772, 1991
    PubMed Google Scholar
  58. Turnbull JE, Fernig DG, Ke Y, Wilkinson MC, Gallagher JT: Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulfate. J Biol Chem 267: 10337–10341, 1992
    PubMed Google Scholar
  59. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT: Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem 269: 11216–11223, 1994
    PubMed Google Scholar
  60. Riccio A, Pedone PV, Lund LR, Olesen T, Olsen HS, Andreasen PA: Transforming growth factor β1-responsive element: Closely associated binding sites for USF and CAAT-binding transcription factor-nuclear factor I in the type I plasminogen activator inhibitor gene. Mol Cell Biol 12: 1846–1855, 1992
    PubMed Google Scholar
  61. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM: Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64: 841–848, 1991
    PubMed Google Scholar
  62. Hill DJ, Logan A: Cell cycle-dependent localization of immunoreactive basic fibroblast growth factor to cytoplasm and nucleus of isolated ovine fetal growth plate chondrocytes. Growth Factors 7: 215–231, 1992
    PubMed Google Scholar
  63. Presta M, Gualandris A, Urbinati C, Rusnati M, Coltrini D, Isacchi A, Caccia P, Bergonzoni L: Subcellular localization and biology activity of Mr 18,000 basic fibroblast growth factor: Site-directed mutagenesis of a putative nuclear translocation sequence. Growth Factors 9: 269–278, 1993
    PubMed Google Scholar
  64. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 81: 631–638, 1993
    PubMed Google Scholar
  65. Renko M, Quarto N, Morimoto T, Rifkin NB: Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 144: 108, 1990
    Google Scholar
  66. Tessier S, Neufeld G: Basic fibroblast growth factor accumulates in the nuclei of various bFGF-producing cell types. J Cell Physiol 145: 310, 1990
    PubMed Google Scholar
  67. Riese J, Zeller P, Dono R: Nucleo-cytoplasmic translocation and secretion of fibroblast growth factor-2 during avian gastrulation. Mech Develop 49: 13–22, 1995
    Google Scholar
  68. Rifkin DB, Moscatelli D, Roghani M, Nagano Y, Quarto N, Klein S, Bikfalvi A: Studies on FGF-2: Nuclear localization and function of high molecular weight forms and receptor binding in the absence of heparin. Mol Repro Dev 39: 102–105, 1994
    Google Scholar
  69. Vilgrain I, Gonzalez AM, Baird A: Phosphorylation of basic fibroblast growth factor (FGF-2) in the nuclei of SK-Hep-1 cells. FEBS Lett 331: 228–232, 1993
    PubMed Google Scholar
  70. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA: The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin collagenase, plasmin and heparanases. J Biol Chem 271: 10079–10086, 1996
    PubMed Google Scholar
  71. Iozzo RV, Cohen IR, Grässel S, Murdoch AD: The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302: 625–639, 1994
    PubMed Google Scholar
  72. Aviezer D, Hecht D, Safran M, Eisinger M, David G, Yayon A: Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79: 1005–1013, 1994
    PubMed Google Scholar
  73. Aviezer D, Iozzo RV, Noonan DM, Yayon A: Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense CDNA. Mol Cell Biol 17: 1938–1946, 1997
    PubMed Google Scholar

Download references